Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2014

Open Access 01-03-2014 | Original Article

Opportunistic breast cancer screening by mammography in Japan for women in their 40s at our preventive medical center: harm or benefit?

Authors: Mari Kikuchi, Hiroko Tsunoda, Tomomi Koyama, Toshiko Kawakita, Koyu Suzuki, Hideko Yamauchi, Osamu Takahashi, Yukihisa Saida

Published in: Breast Cancer | Issue 2/2014

Login to get access

Abstract

Background

After recent revised grading by the US Preventive Services Task Force of mammography (MMG) recommendations for women in their 40s, it is urgent to collect data on the benefits and harm of MMG screenings in Japan. In this paper, we study the actual status and effectiveness of opportunistic breast cancer screening by MMG for women in their 40s.

Methods

From January to December 2008, the total number of opportunistic breast cancer screenings by MMG at our institute was 12823. Of them, 398 (3.1 %) who were diagnosed as category 3 or more on MMG required further exams. The data were compared between two groups (women in their 40s, women aged 50 and older). Recall rate, detection rate of breast cancers, and implementation rate of further exams were evaluated.

Results

Recall rate was 4.0 % (166/4138) for women in their 40s and 2.4 % (166/6949) for women aged 50 and older. Detection rate of breast cancers was higher in women in their 40s (0.56 %) than women aged 50 and older (0.26 %). Non-cancer rate among women receiving invasive examination was higher in women in their 40s (0.76 %) than women aged 50 and older (0.42 %) (p = 0.02). The number of false positives required to detect one true cancer patient was smaller in women in their 40s (4.5) than women aged 50 and older (5.3).

Conclusion

The results from our single institute revealed that opportunistic breast cancer screening by MMG for women in their 40s shows higher net benefits than for women aged 50 and older.
Literature
1.
US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–26.CrossRef
2.
Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:347–60.PubMedCrossRef
3.
Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006;368(2):053–60.
4.
Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med. 2007;146(5):16–26.
5.
Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;146:511–5.PubMedCrossRef
6.
Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med. 2007;146:516–26.PubMedCrossRef
7.
John EM, Phipps AI, Knight JA, Milne RL, Dite GS, Hopper JL, et al. Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry. Int J Cancer. 2007;121:386–94.PubMedCrossRef
8.
Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology. 2005;14:917–38.PubMedCrossRef
9.
Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146:502–10.PubMedCrossRef
10.
Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asia and Western countries? World J Surg. 2010;34:2308–24.PubMedCentralPubMedCrossRef
11.
Japan Association Breast Cancer Screen. Opinion of JABCS to recommendation of screening for breast cancer by U.S. preventive task force. J Jpn Assoc Breast Cancer Screen. 2011;20(1):2.
12.
Yochio K. Harms of breast cancer screening: investigation of false positive cases in mammography screening in Japan. J Jpn Assoc Breast Cancer Screen. 2011;20(1):18–21.
13.
Committee to Revise Mammography Guidelines, editor. The guidelines for mammography. 3rd ed. IGAKU-SHOIN Ltd, Tokyo. 2010.
14.
15.
Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg RD, Carney PA, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol. 1997;169:1001–8.PubMedCrossRef
16.
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med. 2009;151:727–37.PubMedCentralPubMedCrossRef
17.
18.
Metadata
Title
Opportunistic breast cancer screening by mammography in Japan for women in their 40s at our preventive medical center: harm or benefit?
Authors
Mari Kikuchi
Hiroko Tsunoda
Tomomi Koyama
Toshiko Kawakita
Koyu Suzuki
Hideko Yamauchi
Osamu Takahashi
Yukihisa Saida
Publication date
01-03-2014
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0367-9

Other articles of this Issue 2/2014

Breast Cancer 2/2014 Go to the issue

Original Article

Whole breast irradiation for small-sized breasts after conserving surgery: is the field-in-field technique optimal?

Original Article

Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS

Original Article

Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods

Original Article

Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo

Original Article

Appropriate evaluation of and risk factors for radiation dermatitis in breast cancer patients receiving hypofractionated whole-breast irradiation after breast-conserving surgery

Case Report

IgG4-related sclerosing disease of the breast successfully treated by steroid therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits